-
Product Insights
NewNet Present Value Model: BioNTech SE’s BNT-114
Empower your strategies with our Net Present Value Model: BioNTech SE's BNT-114 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.Drug Operating Profit Model
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGS-2 in Werner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGS-2 in Werner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRGS-2 in Werner SyndromeDrug Details:PRG-S-2 is under development for treatment of Werner Syndrome.Report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SIR-0365 in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SIR-0365 in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SIR-0365 in Pain Drug Details:SIR-0365 is under development for the treatment of neurodegenerative disease,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avexitide Acetate in Hypoglycemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avexitide Acetate in Hypoglycemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avexitide Acetate in Hypoglycemia Drug Details:Avexitide acetate is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avexitide Acetate in Hyperinsulinemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avexitide Acetate in Hyperinsulinemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Avexitide Acetate in HyperinsulinemiaDrug Details:Avexitide acetate is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dezapelisib in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dezapelisib in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dezapelisib in B-Cell Non-Hodgkin Lymphoma Drug Details:Dezapelisib (INCB-40093) is under development for...
-
Company Profile
Eiger BioPharmaceuticals Inc – Company Profile
Eiger BioPharmaceuticals Inc (Eiger), formerly known as Celladon Corp, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as Lonafarnib, Peginterferon lambda, avexitide, lonafarnib and ritonavir for hepatitis delta virus (HDV) infection, peginterferon lambda for hepatitis delta virus (HDV) infection, avexitide for post bariatric hypoglycemia (PBH), avexitide for congenital hyperinsulinism (HI) among others. The company also offers post-bariatric hypoglycemia prevention services. It also...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...